Back to top

Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a ...

Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma | CLDI Stock

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Calidi Biotherapeutics, Inc. (CLDI)